Shengchao Xu

1.4k citations
16 papers · 902 indexed · 1 hit paper · h-index 12
Topics
Glioma Diagnosis and Treatment (6 papers)Cancer-related molecular mechanisms research (6 papers)Ferroptosis and cancer prognosis (4 papers)
Partner nations
ChinaUnited States

In The Last Decade

Shengchao Xu

16 papers receiving 894 citations

Hit Papers

Immunotherapy for glioma: Current management and future a...20202026202220242020100200300400500

Peers

Shengchao Xu
Comparison fields: 5 of 80
  • Molecular Biology 516
  • Cancer Research 335
  • Genetics 289
  • Pulmonary and Respiratory Medicine 237
  • Immunology 210
Replace Lu Tang with:
Lu Tang China
Xizhe Li China
Jizong Zhao China
Bakhtiar Yamini United States
Matthew Smith-Cohn United States
K. Jason South Korea
Oltea Sampetrean Japan
Chuan Fang China
Yeri Lee South Korea
Shengchao Xu relative to Lu Tang China Lu Tang's profile →
Citations per field
00.5×1.5×
Lu Tang · 1×
Citations per year

Countries citing papers authored by Shengchao Xu

Since Specialization
Citations

This map shows the geographic impact of Shengchao Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengchao Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengchao Xu more than expected).

Fields of papers citing papers by Shengchao Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengchao Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengchao Xu. The network helps show where Shengchao Xu may publish in the future.

Co-authorship network of co-authors of Shengchao Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Shengchao Xu. A scholar is included among the top collaborators of Shengchao Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengchao Xu. Shengchao Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
#WorkIndexed citations
1 3
2 3
3 17
4 15
5 4
6 14
7 27
8 33
9 88
10 19
11 13
12 10
13 29
14 59
15
Immunotherapy for glioma: Current management and future applicationbreakdown →
501
16 67

About Shengchao Xu

Shengchao Xu is a scholar working on Structural Biology, Cancer Research and Genetics, having authored 16 papers that have together received 902 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (6 papers), Cancer-related molecular mechanisms research (6 papers) and Ferroptosis and cancer prognosis (4 papers). The work is most often cited by research in Genetics (289 citations), Cancer Research (335 citations) and Immunology (210 citations). Shengchao Xu has collaborated with scholars based in China and United States. Frequent co-authors include Zhixiong Liu, Lu Tang, Xizhe Li, Fan Fan, Quan Cheng, Chengke Luo, Gan Dai, Hao Zhang, Zeyu Wang and Ruimin Chang. Their work appears in journals such as Scientific Reports, Frontiers in Immunology and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026